Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Report a Problem to the Center for Biologics Evaluation & Research

Report a Problem to the Center for Biologics Evaluation & Research

                        Biological Product Deviations
          Good Tissue Practices (GTP) & Reporting
          Transfusion/Donation Fatalities
          Direct Recall Classification Program
          Human Cell & Tissue Products (HCT/P) Adverse Reaction Reporting


                        Vaccine Adverse Events Home
          Vaccines, Blood & Biologics
          Safety & Availability (Biologics)
          Report a Problem to the Center for Biologics Evaluation & Research
          Human Cell & Tissue Products (HCT/P) Adverse Reaction ReportingReport a Problem to the Center for Biologics Evaluation & Research Human Cell & Tissue Products (HCT/P) Adverse Reaction Reporting
  
  	
    Share
    Post
    Linkedin

    Email
    PrintHCT/P Establishments (Mandatory Reporting)
	Health Care Professionals, Patients and Consumers (Voluntary Reporting)For HCT/P Establishments (Mandatory Reporting)

On November 24, 2004, the Food and Drug Administration published a final rule that includes requirements in 21 CFR Part 1271.350(a) for reporting certain adverse reactions related to implantation, transplantation, infusion, or transfer of an HCT/P. This rule was effective on May 25, 2005 for HCT/Ps procured on or after the effective date.

HCT/P establishments must maintain complaint files and evaluate each complaint relating to core CGTP requirements.

Establishments are required to:

Investigate any adverse reaction involving a communicable disease related to an HCT/P they made available for distribution and
	Report to FDA any serious adverse reactions involving a communicable disease if it is:Is fatal
	Is life-threatening
	Results in permanent impairment of a body function or permanent damage to body structure or
	Necessitates medical or surgical intervention, including hospitalization.The establishments are required to use the FDA MedWatch mandatory reporting form (Form FDA-3500A) and submit each report to FDA within 15 days of initial receipt of the information. This is the first federal requirement for reporting of adverse reactions from transplanted HCT/Ps.

When reporting an HCT/P adverse reaction please fill out Section C. Suspect Products unless you know that the HCT/P is regulated as a Medical Device, then report in Section D.

Form FDA 3500A - Mandatory Reporting was revised 2/2013The guidance document provides specific information that will assist HCT/P establishments in reporting to FDA using the MedWatch Form FDA 3500A. The Standard Operating Procedure is utilized by FDA in investigating certain adverse reaction reports.

Guidance for Industry: Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271- **3/2016**
	CBER SOPP 8508 - Procedures for Handling Adverse Reaction Reports Related to "361" Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)For Health Care Professionals, Patients and Consumers (Voluntary Reporting)

FDA encourages voluntary reports of HCT/P adverse reactions by health care professionals, patients and consumers to MedWatch. Voluntary reporters may use MedWatch Form FDA 3500 for reporting (see below).

When reporting an HCT/P adverse reaction:

Please fill out Section D. Suspect Products (not Section E. Suspect Medical Device)
	Please provide as much information about the HCT/P as you can
	Name/Type of HCT/P (ex. Achilles Tendon)
		Name of HCT/P distributor or processor
		Lot number, HCT/P Distinct Identification CodeOnline

Voluntary reporters may submit the information online to FDA through the MedWatch Online Voluntary Form (3500). The MedWatch Online application uses Secure Socket Layers (SSL) and Pretty Good Protection (PGP) to encrypt and ensure the security and confidentiality of the MedWatch submission across the Internet.

Form

MedWatch Form FDA 3500 is available for download for voluntary reporters. The form can be submitted by fax or mailed to FDA.

Telephone

Reporting can also be accomplished by calling 1-800-FDA-1088.

E-mail

Questions concerning reporting HCT/P adverse reactions may be sent to TST@cber.fda.gov.

FDA Reporting instructions for Health Care Professionals

FDA Reporting instructions for Consumers

**JCAHO Standards**

On July 1, 2005, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) tissue standards went into effect for any JCAHO accredited organization which stores or issues tissues. These standards include a requirement to report tissue adverse reactions.

All adverse reactions involving tissues, including disease transmission or other complications suspected of being directly related to tissue use, are to be investigated and reported to the HCT/P establishment from which the tissue was received. More information is available on the the JCAHO web site.

                                                                                  Content current as of:
      07/02/2019
              
              
Regulated Product(s)
		 BiologicsHealth Topic(s)
			  HearingReport a Problem to the Center for Biologics Evaluation & Research

          
                        Biological Product Deviations
          Good Tissue Practices (GTP) & Reporting
          Transfusion/Donation Fatalities
          Direct Recall Classification Program
          Human Cell & Tissue Products (HCT/P) Adverse Reaction Reporting


                        Vaccine Adverse Events
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop